<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006421</url>
  </required_header>
  <id_info>
    <org_study_id>010009</org_study_id>
    <secondary_id>01-C-0009</secondary_id>
    <nct_id>NCT00006421</nct_id>
    <nct_alias>NCT00012415</nct_alias>
  </id_info>
  <brief_title>Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study</brief_title>
  <official_title>Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will explore new screening methods for early detection of breast and ovarian
      cancer in women at high risk for these diseases, because they have an altered breast cancer 1
      (BRCA1) or breast cancer 2 (BRCA2) gene. It will also try to determine if breast tissue
      characteristics in women with a BRCA1 or BRCA2 mutation differ from those in women with a
      normal gene.

      Premenopausal women between 25 and 45 years of age who have participated in National Cancer
      Institute studies for families or individuals at high genetic risk of cancer (78-C-0039 or
      99-C-0081) and who have at least a 50 percent probability of carrying an altered BRCA1 or
      BRCA2 gene may be eligible for this study.

      At the first visit, participants will have from 4 to 24 tablespoons of blood drawn and will
      be interviewed about breast and ovarian cancer risk factors, family and personal history of
      cancer, history of pregnancies, use of oral contraceptives and other hormones and drugs, and
      previous surgery on the breasts and ovaries. In addition, they will undergo the following
      procedures:

      Routine breast and ovarian cancer screening for high-risk women, including a mammogram,
      breast and pelvic exam, instruction in breast self-examination, CA 125 blood test and
      transvaginal ultrasound of the ovaries.

      Magnetic Resonance Imaging (MRI) of the breast MRI uses a strong magnetic field to show
      structural and chemical changes in tissues.

      Breast Duct Lavage In this procedure samples of fluid and cells from the lining of the breast
      milk ducts are collected to look for cancerous or pre-cancerous cell changes.

      Positron Emission Tomography (PET) scan PET scanning will be done only in participants whose
      mammogram or MRI findings require additional evaluation. This diagnostic test is based on
      differences in how cells take up and use glucose (sugar), one of the body s main fuels.

      Annual follow-up visits will be scheduled for 3 years and will include routine high-risk
      screening as described above, blood draw, update of family history and risk factors, breast
      MRI, breast duct lavage and, if there are changes on the MRI or mammogram that need further
      evaluation, the PET will be repeated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Women who carry mutations in genes such as BRCA1/2 have a higher lifetime risk of breast
           cancer (BC) and are at risk of developing BC at earlier ages than women in the general
           population.

        -  Prophylactic mastectomy and/or oophorectomy may be used to decrease risk and intensified
           mammographic and magnetic resonance imaging (MRI) surveillance may allow earlier
           diagnosis; however, prophylactic mastectomy has not been shown to convey survival
           advantage over more conservative management.

        -  Greater breast tissue density and low BC incidence result in a lower positive predictive
           value of mammography in premenopausal women as compared to postmenopausal women
           (PPV=0.04 for women aged 40-49).

        -  This study explores whether high-risk breast imaging phenotypes may be identified by
           comparing imaging characteristics of mutation carriers/non-carriers using two imaging
           modalities: mammography and MRI.

        -  Nipple Aspiration Fluid collection (NAF) and breast duct lavage will be used to obtain
           cytologic materials which may be used as an adjunct to breast imaging for the early
           detection of epithelial atypia and pre-invasive cancer.

      Objectives:

        -  Compare four outcomes including two mammographic density measures (qualitative and
           semiquantitative), fibroglandular volume measure using MRI, and contrast enhancement
           measure using MRI (both semiquantitative) in mutation carriers/non-carriers to improve
           lesion detection

        -  Explore non-ionizing approaches (MRI) to BC screening because the effects of ionizing
           radiation due to mammography are unknown.

        -  Use NAF and/or BDL to obtain epithelial cell samples and correlate cytologic and imaging
           findings.

        -  Gather prospective data on the transformation from
           normal/hyperplastic/pre-invasive/invasive disease in BRCA1/2 mutation
           carriers/non-carriers through molecular/genetic studies of breast tissue (via biopsy of
           radiographic abnormalities) or breast fluid (via BDL and/or nipple aspiration) and
           develop molecular markers for early detection of epithelial atypia/pre-invasive cancer.

        -  Assess the psychosocial impact of participation in a BC screening program.

      Eligibility:

        -  Women 25-56 years of age carrying a known BRCA1/2 deleterious mutation.

        -  Women between the ages of 25 -56 who are first- or second- degree relatives of
           individuals with a deleterious BRCA1/2 mutation.

        -  Women aged 25-56 who are first- or second- degree relatives of individuals with
           BRCA-associated cancers in families with documented BRCA mutations.

      Design:

        -  Prospective cohort study of 200 women to gather data on the evolution of epithelial
           cell/molecular changes in BRCA1/2 mutation carriers, by collecting/analyzing NAF, BDL
           fluid, biopsy tissues (when indicated), and serum/lymphocytes; samples are stored for
           future studies.

        -  Women complete questionnaires and undergo breast/pelvis examination, transvaginal
           ultrasonography, serum pregnancy test, fasting glucose, electrolytes, BUN, creatinine
           and CA 125. Standard four view mammogram and breast MRI are performed on study entry and
           annually for three additional years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1, 2000</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare 4 outcomes including two mammographic density measures (qual and semi-quant), fibroglandular vol measure using MRI, &amp;amp; contrast enhancement measure using MRI (both semiquantitative) in mutation carriers/non-carriers to improve les...</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Use NAF and/or BDL to obtain epithelial cell samples and correlate cytologic and imaging findings.</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gather prospective data on the transformation from normal/hyperplastic/pre-invasive/invasive disease in BRCA1/2 mutation carriers/non-carriers through molecular/genetic studies of breast tissue (via biopsy of radiographic abnormalities) or breas...</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the psychosocial impact of participation in a BC screening program.</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA - Annual Follow-up Study:

        To participate in the Annual Follow-up Study, a woman must:

        Be at least 25 years of age (or 5 years younger than the age at diagnosis of the youngest
        family member with a tumor associated with the Breast-Ovarian Cancer Syndrome) and less
        than 56 years of age.

        Must be:

        A known BRCA1 or BRCA2 deleterious mutation carrier

        OR

        A first- or second- degree relative of an individual known to carry a deleterious BRCA1 or
        BRCA2 mutation

        OR

        A first- or second- degree relative of an individual with a tumor associated with the
        Breast-Ovarian Cancer Syndrome in a family with a known BRCA mutation.

        Have undergone genetic counseling and risk assessment.

        Agree to release of genetic test result for stratification purposes, whether or not she has
        chosen to receive individual test results for clinical decision-making.

        Have an ECOG performance status of 0-1.

        Be able to provide informed consent.

        Have at least one non-irradiated breast.

        EXCLUSION CRITERIA - Annual Follow-up Study:

        Any of the following will result in exclusion from the Annual Follow-up Study:

        Pregnancy or lactation within 6 months of enrollment.

        Abnormal CA-125 level.

        Bilateral breast cancer, ovarian (any stage) or breast cancer (Stage IIB or worse) unless
        relapse free for 5 years prior to the time of enrollment.

        Patients with DCIS, Stage I and Stage II breast cancer are eligible provided that it has
        been at least 6 months from the completion of primary therapy (surgery, radiation, and
        chemotherapy as applicable). Tamoxifen and aromatase inhibitor adjuvant therapy is allowed.

        Patients with DCIS, Stage I and Stage II breast cancer who have had a local relapse after
        primary treatment are not eligible unless they have been relapse free for 5 years prior to
        the time of enrollment.

        History of other invasive cancer unless relapse free for 5 years prior to the time of
        enrollment. Non-Melanoma skin cancer or cervical carcinoma in situ are excepted.

        Previous bilateral mastectomy or bilateral radiation therapy.

        Weigh over 136 kilograms.

        Allergy to gadolinium.

        Allergy to lidocaine or Marcaine (bupivacaine). (excluded from breast duct lavage only).

        Subareolar or other surgery of the breast to be studied which might disrupt the ductal
        systems. For example, papilloma resection, biopsy or fine needle aspirations (FNAs) within
        2 cm of the nipple might disrupt the ductal systems. Biopsies or FNAs greater than 2 cm
        from the nipple are acceptable. (Excluded from ductal lavage only)

        A breast implant or prior silicone injections in the breast to be studied. (Exclude from
        breast ductal lavage only)

        Active infections or inflammation in a breast to be studied. (breast ductal lavage only)

        Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would
        preclude informed consent or ability to participate in clinical research.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer T Loud, C.R.N.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2001-C-0009.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Koehly LM, Peters JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, Loud JT, Greene MH. Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health. 2009 Dec;99(12):2203-9. doi: 10.2105/AJPH.2008.154096. Epub 2009 Oct 15.</citation>
    <PMID>19833996</PMID>
  </reference>
  <reference>
    <citation>Loud JT, Thi√©baut AC, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH. Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1243-51. doi: 10.1158/1055-9965.EPI-08-0795. Epub 2009 Mar 31.</citation>
    <PMID>19336560</PMID>
  </reference>
  <reference>
    <citation>Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH. Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat. 2010 Aug;123(1):245-55. doi: 10.1007/s10549-010-0749-7. Epub 2010 Feb 4.</citation>
    <PMID>20130984</PMID>
  </reference>
  <verification_date>June 19, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2000</study_first_submitted>
  <study_first_submitted_qc>October 27, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2000</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <keyword>Breast MRI</keyword>
  <keyword>Nipple Aspirate Fluid</keyword>
  <keyword>Transvaginal ultrasound</keyword>
  <keyword>Ductal lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

